WO2022056368A1 - Crystalline forms of a compound for the targeted degradation of estrogen receptor - Google Patents

Crystalline forms of a compound for the targeted degradation of estrogen receptor Download PDF

Info

Publication number
WO2022056368A1
WO2022056368A1 PCT/US2021/050046 US2021050046W WO2022056368A1 WO 2022056368 A1 WO2022056368 A1 WO 2022056368A1 US 2021050046 W US2021050046 W US 2021050046W WO 2022056368 A1 WO2022056368 A1 WO 2022056368A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymorph
compound
radiation
disease
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/050046
Other languages
English (en)
French (fr)
Inventor
Katharine Victoria BOULTON
Chungpin Herman CHEN
III Royal J. HASKELL
Hayley REECE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arvinas Operations Inc
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP21787193.8A priority Critical patent/EP4211128A1/en
Priority to JP2023516491A priority patent/JP2023541434A/ja
Priority to MX2023002979A priority patent/MX2023002979A/es
Priority to IL301155A priority patent/IL301155A/en
Priority to PE2023001149A priority patent/PE20231555A1/es
Priority to CA3194954A priority patent/CA3194954A1/en
Priority to AU2021342287A priority patent/AU2021342287A1/en
Priority to CN202180070126.4A priority patent/CN116390916A/zh
Priority to CR20230162A priority patent/CR20230162A/es
Priority to BR112023004656A priority patent/BR112023004656A2/pt
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Priority to KR1020237011950A priority patent/KR20230069144A/ko
Publication of WO2022056368A1 publication Critical patent/WO2022056368A1/en
Priority to DO2023000052A priority patent/DOP2023000052A/es
Anticipated expiration legal-status Critical
Priority to CONC2023/0004435A priority patent/CO2023004435A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • E3 ubiquitin ligases confer substrate specificity for ubiquitination, and therefore are attractive therapeutic targets due to their specificity for certain protein substrates.
  • the development of ligands of E3 ligases has proven challenging, in part because they must disrupt protein-protein interactions.
  • recent developments have provided specific ligands which bind to these ligases. For example, since the discovery of nutlins, the first small molecule E3 ligase inhibitors, additional compounds have been reported that target E3 ligases.
  • E3 ligase with particular therapeutic potential is cereblon, a protein that in humans is encoded by the CRBN gene.
  • CRBN orthologs are highly conserved from plants to humans, indicating its physiological importance.
  • Cereblon forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1), Cullin-4A (CUL4A), and regulator of cullins 1 (ROC1). This complex ubiquitinates several other proteins.
  • DDB1 DNA binding protein 1
  • CUL4A Cullin-4A
  • ROC1 regulator of cullins 1
  • This complex ubiquitinates several other proteins.
  • cereblon ubiquitination of target proteins results in increased levels of fibroblast growth factor 8 (FGF8) and fibroblast growth factor 10 (FGF10).
  • FGF8 fibroblast growth factor 8
  • FGF10 fibroblast growth factor 10
  • FGF8 in turn, regulates several developmental processes, such as limb and auditory vesicle formation.
  • the net result is that this ubiquitin ligase complex is important for limb outgrowth in embryos.
  • DDB 1 forms a complex with DDB2, which functions as a DNA damage-binding protein.
  • Thalidomide which has been approved for the treatment of a number of immunological indications, has also been approved for the treatment of certain neoplastic diseases, including multiple myeloma.
  • thalidomide and several of its analogs are currently under investigation for use in treating a variety of other types of cancer. While the precise mechanism of thalidomide’s anti -tumor activity is still emerging, it is known to inhibit angiogenesis. Recent literature discussing the biology of the imides includes Lu et al. Science 343, 305 (2014) and Kroenke et al. Science 343, 301 (2014).
  • thalidomide and its analogs are known to bind cereblon, and to alter the specificity of the complex to induce the ubiquitination and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), which are transcription factors essential for multiple myeloma growth.
  • IKZF1 and Aiolos IKZF3
  • the estrogen receptor (ER) is a member of the nuclear hormone receptor family and functions as a ligand-activated transcription factor involved with the up and down regulation of gene expression.
  • the natural hormone for the ER is 17-beta-estradiol (E2) and closely related metabolites. Binding of estradiol to the ER causes a dimerization of the receptor and the dimer in turn binds to estrogen response elements (EREs) on DNA.
  • E2 17-beta-estradiol
  • E2 17-beta-estradiol
  • E2 17-beta-estradiol
  • Binding of estradiol to the ER causes a dimerization of the receptor and the dimer in turn binds to estrogen response elements (EREs) on DNA.
  • ERE estrogen response elements
  • the ER-DNA complex recruits other transcription factors responsible for the transcription of DNA downstream from the ERE into mRNA, which is eventually translated into protein.
  • the interaction of ER with DNA may be indirect through
  • estrogen-dependent diseases A variety of diseases have their etiology and/or pathology mediated by the ER. Collectively these diseases are called estrogen-dependent diseases. Estrogens are critical for sexual development in females. In addition, estrogens play an important role in maintaining bone density, regulation of blood lipid levels, and appear to have neuroprotective effects. Consequently, decreased estrogen production in post-menopausal women is associated with a number of diseases such as osteoporosis, atherosclerosis, depression and cognitive disorders. Conversely, certain types of proliferative diseases such as breast and uterine cancer and endometriosis are stimulated by estrogens and therefore anti-estrogens (i.e. estrogen antagonists) may have utility in the prevention and treatment of these types of disorders.
  • anti-estrogens i.e. estrogen antagonists
  • ER There are two different forms of the ER, usually referred to as a and P, each encoded by a separate gene (ESRI and ESR2, respectively). Both ERs are widely expressed in different tissue types, but there are some notable differences in their expression patterns.
  • the ERa is found in endometrium, breast cancer cells, ovarian stroma cells, and the hypothalamus.
  • ERa protein is found in the epithelium of the efferent ducts.
  • the expression of the ER[> protein has been documented in kidney, brain, bone, heart, lungs, intestinal mucosa, prostate, and endothelial cells. Development of selective ligands for one form or the other may therefore preserve the beneficial aspects of estrogen.
  • Estrogens act as endocrine growth factors for at least one-third of breast cancers, and depriving the tumor of this stimulus is a recognized therapy for advanced disease in premenopausal women. This is achieved by the ablation of ovarian function through surgical, radiotherapeutic, or medical means and, in postmenopausal women, by the use of aromatase inhibitors.
  • estrogen withdrawal is to antagonize estrogen with antiestrogens.
  • drugs that bind to and compete for ER present in estrogen-responsive tissues.
  • Conventional non-steroidal anti-estrogens such as tamoxifen, compete efficiently for ER binding, but their effectiveness is often limited by the partial agonism they display, which results in an incomplete blockade of estrogen-mediated activity.
  • a specific or "pure" anti-estrogen with high affinity for ER and without any agonist effect may have advantages over conventional non-steroidal anti-estrogens in the treatment of estrogen-dependent disease.
  • Fulvestrant is the first of a new class of potent pure anti-estrogens and is completely free of the partial agonist, estrogen-like activity, associated with currently available anti-estrogens like tamoxifen.
  • the compound made and used according to the present invention is (S)-3-(5-(4-((l-(4-)
  • Compound A is under development as a PROTAC® protein degrader that targets estrogen receptor (ER) for the potential treatment of breast cancer.
  • Compound A has been shown to be a useful modulator of targeted protein ubiquitination and degradation via the ubiquitin- proteasome pathway.
  • the present disclosure provides several crystalline forms (polymorphs) and an amorphous form of Compound A.
  • the present disclosure provides a polymorph (“Form I”) of Compound A characterized by an X-ray powder diffraction pattern including peaks at about 13.9 °29, about 16.4 °29, and about 17.9 °29 using Cu Ka radiation at an x-ray wavelength of 1.5406 A.
  • the present disclosure provides a polymorph (“Form II”) of Compound A characterized by an X-ray powder diffraction pattern including a peak at about 10.0 °29, about 16.3 °29 and about 17.5 °29 using Cu Ka radiation at an x-ray wavelength of 1.5406 A.
  • the present disclosure provides a polymorph (“Form III”) of Compound A characterized by an X-ray powder diffraction pattern including a peak at about 8.8 °29, about 10.7 °29 and 18.2 °29 using Cu Ka radiation at an x-ray wavelength of 1.5406 A.
  • the present disclosure provides a polymorph (“Form IV”) of Compound A characterized by an X-ray powder diffraction pattern including peaks at about 10.5 °29, about 14.5 °29, and about 16.9 °29 at an x-ray wavelength of 1.5406 A.
  • the present disclosure provides a method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a polymorph and/or amorphous form of Compound A.
  • the disease or disorder is associated with ER activity, overactivity, constitutive activity, expression, overexpression, or accumulation and aggregation.
  • the disease or disorder is associated with ER activity.
  • the disease or disorder is associated with ER overactivity.
  • the disease or disorder is associated with ER constitutive activity.
  • the disease or disorder is associated with ER expression.
  • the disease or disorder is associated with ER overexpression.
  • the disease or disorder is associated with ER accumulation and aggregation.
  • the disease or disorder is cancer or a neoplasia associated with ER activity, overactivity, constitutive activity, expression, overexpression, or accumulation and aggregation.
  • the disease or disorder is breast cancer, ovarian cancer, endometrial cancer or uterine cancer. In some embodiments, the disease or disorder is endometriosis.
  • the present disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a polymorph and/or amorphous form of Compound A wherein the composition is effective in treating or ameliorating at least one symptom of the disease or disorder.
  • the disease or disorder is causally associated with ER activity, overactivity, constitutive activity, expression, overexpression, or accumulation and aggregation.
  • the disease or disorder is cancer or a neoplasia causally associated with ER activity, overactivity, constitutive activity, expression, overexpression, or accumulation and aggregation.
  • the disease or disorder is breast cancer, ovarian cancer, endometrial cancer or uterine cancer.
  • the disease or disorder is endometriosis.
  • the present disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of an amorphous form of Compound A and a pharmaceutically acceptable dispersing agent.
  • the pharmaceutically acceptable dispersing agent further comprises a pharmaceutically acceptable additive.
  • the pharmaceutically acceptable dispersing agent is hydroxypropyl methylcellulose (HPMC).
  • the pharmaceutically acceptable additive is D-a-tocopheryl polyethylene glycol succinate (Vitamin E TPGS or TPGS).
  • a polymorph of the invention is the preferred form for the storing of Compound A in bulk prior to converting to amorphous Compound A.
  • the polymorph of Compound A is Form I.
  • the polymorph of Compound A is Form II.
  • the polymorph of Compound A is Form III.
  • the polymorph of Compound A is Form IV.
  • the form for storing of Compound A in bulk is a mixture of one or more solid forms (e.g. polymorphs or amorphous form) of Compound A disclosed herein.
  • the form for storing of Compound A in bulk is a mixture of Form I and the amorphous form.
  • the form for storing of Compound A in bulk is a mixture of Form I and Form II. In some embodiments, the form for storing of Compound A in bulk is a mixture of Form I and Form III. In some embodiments, the preferred form for storing of Compound A in bulk is a mixture of Form I and Form IV. [0024] In another aspect, the present disclosure provides the use of a polymorph and/or amorphous form of Compound A in the manufacture of a medicament for the treatment of a disease or disorder. In some embodiments, the disease or disorder is associated with ER activity, overactivity, constitutive activity, expression, overexpression, or accumulation and aggregation.
  • the disease or disorder is cancer or a neoplasia associated with ER activity, overactivity, constitutive activity, expression, overexpression, or accumulation and aggregation.
  • the disease or disorder is breast cancer, ovarian cancer, endometrial cancer or uterine cancer. In some embodiments, the disease or disorder is endometriosis.
  • the present disclosure provides a polymorph and/or amorphous form of Compound A for use in medicine.
  • the present disclosure provides a polymorph and/or amorphous form of Compound A for use in the treatment of a disease or disorder.
  • the disease or disorder is associated with ER activity, overactivity, constitutive activity, expression, overexpression, or accumulation and aggregation.
  • the disease or disorder is cancer or a neoplasia associated with ER activity, overactivity, constitutive activity, expression, overexpression, or accumulation and aggregation.
  • the disease or disorder is breast cancer, ovarian cancer, endometrial cancer or uterine cancer. In some embodiments, the disease or disorder is endometriosis.
  • the present disclosure provides a method of making the Form I polymorph of Compound A, comprising recrystallizing Compound A from a solvent.
  • the solvent is acetone, 1 -butanol, 2-ethoxy ethanol, ethanol, ethyl acetate, isopropyl acetate, methanol, methyl ethyl ketone, 1 -propanol, 2-propanol, or a mixture of ethanol and water.
  • the present disclosure provides a method of making the Form II polymorph of Compound A, comprising recrystallizing Compound A from a solvent.
  • the solvent is dichloromethane or a mixture of acetone and water.
  • the present disclosure provides a method of making the Form III polymorph of Compound A, comprising recrystallizing Compound A from a solvent.
  • the solvent is acetonitrile.
  • the present disclosure provides a method of making the Form IV polymorph of Compound A, comprising crash-cooling Compound A from a solvent.
  • the solvent is a mixture of dichloromethane and methanol.
  • the present disclosure provides a method of making the Form IV polymorph of Compound A, comprising addition of an anti-solvent to a solution of Compound A from a solvent.
  • the solvent comprises a mixture of dichloromethane and methanol.
  • the anti-solvent is tert-butyl methyl ether.
  • FIG. 1 A shows the XRPD spectrum of a sample of the Form I polymorph of Compound A.
  • the diffractogram is from material recovered from methyl ethyl ketone.
  • FIG. IB shows a TG/DT plot of a sample of the Form I polymorph of Compound A.
  • the TG plot begins at the top left, and the DT plot begins at the bottom left.
  • FIG. 1C shows PLM images of the Form I polymorph of Compound A. Samples in this figure were recovered from methanol.
  • FIG. 2 A shows the XRPD spectrum of a sample of Form II of Compound A.
  • the diffractogram is from material recovered from dichloromethane.
  • FIG. 2B shows a TG/DT plot of a sample of the Form II polymorph of Compound A.
  • the TG plot begins at the top left, and the DT plot begins at the bottom left.
  • FIG. 2C shows PLM images of the Form II polymorph of Compound A. Samples in this figure were recovered from dichloromethane.
  • FIG. 3A shows the XRPD spectrum of a sample of the Form III polymorph of Compound A.
  • the diffractogram is from material recovered from acetonitrile.
  • FIG. 3B shows a TG/DT plot of a sample of the Form III polymorph of Compound A.
  • the TG plot begins at the top left, and the DT plot begins at the bottom left.
  • FIG. 3C shows PLM images of the Form III polymorph of Compound A. Samples in this figure were recovered from acetonitrile.
  • FIG. 4 A shows the XRPD spectrum of a sample of the Form IV polymorph of Compound A.
  • the diffractogram is from material recovered from dichloromethane:methanol (25:75 v/v) after crash cooling.
  • FIG. 4B shows a shows a TG/DT plot of a sample of the Form IV polymorph of Compound A.
  • the TG plot begins at the top left, and the DT plot begins at the bottom left.
  • FIG. 4C shows PLM images of the Form IV polymorph of Compound A. Samples in this figure were recovered from dichloromethane:methanol (25:75 v/v).
  • XRPD X-ray powder diffraction. Unless otherwise specified, all XRPD peaks and patterns are given in °29 using Cu Kai radiation at a wavelength of 1.5406 A.
  • TG and TGA are understood to mean thermogravimetry or thermogravimetric analysis.
  • DT or “DTA” are understood to mean differential thermal analysis.
  • TG/DT and “TG/DTA” are understood to mean thermogravimetry/differential thermal analysis.
  • PLM polarized light microscopy
  • peak values “about” can indicate a peak value at exactly the disclosed peak value.
  • the term “substantially” means greater than 85% (i.e., greater than 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%).
  • substantially similar as used herein with regards to an analytical spectrum, such as an XRPD pattern, means that a spectrum resembles the reference spectrum to a great degree in both the peak locations and their relative intensities.
  • two spectra may be regarded as “substantially similar” when the two spectra share defining characteristics sufficient to differentiate them from a spectrum obtained for a different solid form.
  • spectra or characterization data that are substantially similar to those of a reference crystalline form, amorphous form, or mixture thereof, are understood by those of ordinary skill in the art to correspond to the same crystalline form, amorphous form, or mixture thereof as the particular reference.
  • characterization data points may vary to a reasonable extent while still describing a given solid form, due to, for example, experimental error and routine sample-to- sample analysis.
  • a reference to "A and/or B", when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
  • the phrase "at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
  • This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified.
  • At least one of A and B can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
  • the crystals of the present invention may be in e.g., a triclinic, monoclinic, orthorhombic, tetragonal, rhombohedral, hexagonal or cubic crystal form or mixtures thereof.
  • the crystals of the present invention are substantially free of other forms, e.g., free of amorphous or other crystal forms.
  • amorphous form refers to solids of disordered arrangements of molecules and do not possess a distinguishable crystal lattice.
  • co-administration and “co-administering” or “combination therapy” refer to both concurrent administration (administration of two or more therapeutic agents at the same time) and time varied administration (administration of one or more therapeutic agents at a time different from that of the administration of an additional therapeutic agent or agents), as long as the therapeutic agents are present in the patient to some extent, preferably at effective amounts, at the same time.
  • one or more of the present compounds described herein are co-administered in combination with at least one additional bioactive agent, especially including an anticancer agent.
  • the co-administration of compounds results in improved activity or synergistic activity and/or therapy, including anticancer activity.
  • compound refers to any specific chemical compound disclosed herein, including deuterated forms thereof where applicable, in context.
  • Deuterated small molecules contemplated are those in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by deuterium. Unless the context indicates otherwise, the term compound refers to Compound A.
  • ubiquitin ligase refers to a family of proteins that facilitate the transfer of ubiquitin to a specific substrate protein, targeting the substrate protein for degradation.
  • cereblon is an E3 ubiquitin ligase protein that alone or in combination with an E2 ubiquitin- conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein.
  • E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins.
  • the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first; a third is attached to the second, and so forth. Such polyubiquitination marks the target proteins for degradation by the proteasome.
  • patient or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present disclosure is provided.
  • the term “patient” refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc.
  • the term “patient” refers to a human patient unless otherwise stated or implied from the context of the use of the term.
  • therapeutically effective amount and the like, as used herein, indicate an amount necessary to administer to a patient, or to a cell, tissue, or organ of a patient, to achieve a therapeutic effect, such as an ameliorating or alternatively a curative effect.
  • the therapeutically effective amount is sufficient to elicit the biological or medical response of a cell, tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor, or clinician. Determination of the appropriate therapeutically effective amount is within the routine level of skill in the art.
  • Compound A can be prepared according to the methods disclosed in US Patent No. 10,647,698, which is incorporated herein for all purposes.
  • the Form I polymorph of Compound A can be prepared by crystallization from a number of solvents. For instance, Form I was recovered from each of the following solvents by temperature cycling between ambient temperature (about 22°C) and 40°C in 4 hour cycles for 72 hours: acetone, 1 -butanol, 2-ethoxy ethanol, ethanol, ethyl acetate, isopropyl acetate, methanol, methyl ethyl ketone, 1 -propanol, 2-propanol, and ethanol: water (90: 10 v/v).
  • An XRPD spectrum of Form I, recovered from methyl ethyl ketone is shown in FIG. 1 A, obtained using Cu Ka radiation.
  • this application provides a method of making Form I of the polymorph as disclosed herein, comprising recrystallizing Compound A from a solvent.
  • the solvent is acetone, 1 -butanol, 2-ethoxy ethanol, ethanol, ethyl acetate, isopropyl acetate, methanol, methyl ethyl ketone, 1 -propanol, 2-propanol, or a mixture of ethanol and water.
  • the solvent is acetone.
  • the solvent is 1-butanol.
  • the solvent is 2-ethoxy ethanol.
  • the solvent is ethanol.
  • the solvent is ethyl acetate. In some embodiments, the solvent is isopropyl acetate. In some embodiments, the solvent is methanol. In some embodiments, the solvent is methyl ethyl ketone. In some embodiments, the solvent is 1 -propanol. In some embodiments, the solvent is 2-propanol. In some embodiments, the solvent is a mixture of ethanol/water. In some embodiments, the ratio of ethanol to water is between about 85: 15 (v/v) and about 95:5 (v/v). In some embodiments, the ratio of ethanol to water is between 85: 15 (v/v) and 95:5 (v/v). In some embodiments, the ratio of ethanol to water is about 90: 10 (v/v). In some embodiments, the water is deionized water.
  • Form I can be characterized by the XRPD peaks shown in FIG. 1 A.
  • Form I can be characterized by an XRPD peak at about 17.9 °20 (e.g. 17.9 ⁇ 0.2 °20, 17.9 ⁇ 0.1 °20, or 17.9 ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be further characterized by XRPD peaks at about 13.9 °29 and/or about 16.4 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be further characterized by XRPD peaks at about 16.2 °29, about 18.5 °29, about 16.8 °29, about 14.5 °29, and/or about 13.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by an XRPD peak at about 17.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29 or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by an XRPD peak at about 13.9 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 17.9°29 and about 13.9 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.5 °29, about 17.9 °29 and about 13.9 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 14.3 °29, about 17.9 °29 and about 13.9 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 14.5 °29, about 17.9 °29 and about 13.9 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 16.2 °29, about 17.9 °29 and about 13.9 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 16.4°29, about 17.9 °29 and about 13.9 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 16.8°20, about 17.9 °20 and about 13.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 18.5 °29, about 17.9 °29 and about 13.9 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 18.9 °29, about 17.9 °29 and about 13.9 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 16.4 °29, about 16.8 °20, about 18.5 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 16.4 °29, about 16.8 °20, about 17.9 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 16.4 °29, about 16.8 °20, about 17.9 °20, and about 18.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 16.2 °29, about 17.9 °20, about 18.5 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 16.2 °29, about 16.8 °20, about 18.5 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 16.2 °29, about 16.8 °20, about 17.9 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 16.2 °29, about 16.8 °20, about 17.9 °20, and about 18.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 16.2 °29, about 16.4 °20, about 18.5 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 16.2 °29, about 16.4 °20, about 17.9 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 16.2 °29, about 16.4 °20, about 17.9 °20, and about 18.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 16.2 °29, about 16.4 °20, about 16.8 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 16.2 °29, about 16.4 °20, about 16.8 °20, and about 18.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 16.2 °29, about 16.4 °20, about 16.8 °20, and about 17.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 13.9 °29, about 17.9 °20, about 18.5 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.8 °20, about 18.5 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.8 °20, about 17.9 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.8 °20, about 17.9 °20, and about 18.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.4 °20, about 18.5 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.4 °20, about 17.9 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.4 °20, about 17.9 °20, and about 18.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.4 °20, about 16.8 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.4 °20, about 16.8 °20, and about 18.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.4 °20, about 16.8 °20, and about 17.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.2 °20, about 18.5 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.2 °20, about 17.9 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.2 °20, about 17.9 °20, and about 18.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.2 °20, about 16.8 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.2 °20, about 16.8 °20, and about 18.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.2 °20, about 16.8 °20, and about 17.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.2 °20, about 16.4 °20, and about 20.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.2 °20, about 16.4 °20, and about 18.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation). In some embodiments, Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.2 °20, about 16.4 °20, and about 17.9 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by XRPD peaks at about 13.9 °29, about 16.2 °20, about 16.4 °20, and about 16.8 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by one or more XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°29, about 18.5°29, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°29, about 18.5°29, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by one XRPD peak selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°29, about 18.5°29, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • XRPD peak selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°29, about 18.5°29, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by two XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°20, about 14.3°20, about 14.5°20, about 16.2°20, about 16.4°20, about 16.8°20, about 18.5°20, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by three XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°20, about 18.5°20, about 18.9°20, and about 20.9°20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20;
  • Form I can be characterized by four XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°29, about 18.5°29, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by five XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°29, about 18.5°29, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by six XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°29, about 18.5°29, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by seven XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°20, about 18.5°20, about 18.9°20, and about 20.9°20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can be characterized by eight XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°29, about 18.5°29, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by nine XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°29, about 18.5°29, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by ten XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°20, about 14.3°20, about 14.5°20, about 16.2°20, about 16.4°20, about 16.8°20, about 18.5°20, about 18.9°29, and about 20.9°29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form I can be characterized by eleven XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°20, about 18.5°20, about 18.9°20, and about 20.9°20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • eleven XRPD peaks selected from about 17.9°29, about 13.9°29, about 13.5°29, about 14.3°29, about 14.5°29, about 16.2°29, about 16.4°29, about 16.8°20, about 18.5°20, about 18.9°20, and about 20.9°20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form I can have one, two, three, four, five, six, seven, eight, nine, ten, eleven, or more, peaks as those listed in Table 1.
  • FIG. IB is a TG/DT plot of a sample of Form I.
  • TG showed a weight loss of about 1% up to the melt at about 250°C. This was followed by 0.6% weight loss during the melt, and a final weight loss of 0.4% can be seen up to about 350°C.
  • An endothermic event was noted in the DT trace with an onset of about 259 °C, with a peak at about 266 °C.
  • Form I is characterized by a weight loss of about 1% between about 25°C and about 250°C.
  • Form I is characterized by an endothermic event, as measured by DT, with an onset of about 259°C.
  • Form I is characterized by an endothermic event, as measured by DT, with a peak at about 166 °C. In some embodiments, Form I is characterized by an endothermic event, as measured by DT, with an onset of about 259 °C and a peak at about 266 °C. In some embodiments, weight loss is determined by thermogravimetric analysis. In some embodiments, thermogravimetric analysis is conducted substantially as shown in Example 1. In some embodiments, endothermic events are calculated by differential thermal analysis. In some embodiments, differential thermal analysis is conducted substantially as shown in Example 1. In some embodiments, thermogravimetric analysis and differential thermal analysis are conducted simultaneously.
  • FIG. 1C shows PLM images of Form I recovered from methanol.
  • PLM indicated the material to be birefringent with irregular, lath-like morphology.
  • Form I is characterized by birefringent material with irregular, lath-like morphology.
  • Form II of Compound A can be prepared by crystallization from a number of solvents. For instance, Form II was recovered by temperature cycling between ambient (about 22°C) and 40°C in 4 hour cycles for 72 hours from di chloromethane and also from acetone:water (90:10 v/v). An XRPD spectrum of Form II, recovered from di chloromethane is shown in FIG. 2A, obtained using Cu Ka radiation.
  • this application provides a method of making Form II of Compound A as disclosed herein, comprising recrystallizing Compound A from a solvent.
  • the solvent is selected from dichloromethane and a mixture of acetone and water.
  • the solvent is dichloromethane.
  • the solvent is a mixture of acetone and water.
  • the ratio of acetone to water is between about 85: 15 (v/v) and about 95:5 (v/v).
  • the ratio of acetone to water is between 85: 15 (v/v) and 95:5 (v/v).
  • the ratio of acetone to water is about 90: 10 (v/v).
  • the water is deionized water.
  • Form II can be characterized by the XRPD peaks shown in FIG. 2A.
  • Form II can be characterized by an XRPD peak at about 17.5°29 (e.g. 17.5 ⁇ 0.2 °29, 17.5 ⁇ 0.1 °29, or 17.5 ⁇ 0.0 °20).
  • Form II can be further characterized by XRPD peaks at about 9.2 °29, about 10.0 °29, about 16.3 °29, and/or about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be further characterized by XRPD peaks at about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, and/or about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 9.2 °29 and about 17.5 °20 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 10.0 °20 and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 16.3 °29 and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 18.1 °29 and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 12.5 °29 and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 14.1 °29 and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 15.7 °29 and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 16.9 °29 and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 19.1 °29 and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 19.6 °29 and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 18.1 °29 and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 16.3 °29, about 17.5 °29, and about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 10.0 °29, about 17.5 °29, and about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 10.0 °29, about 16.3 °29, and about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 10.0 °29, about 16.3 °29, and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 9.2 °29, about 17.5 °29, and about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 9.2 °29, about 16.3 °29, and about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 9.2 °29, about 16.3 °29, and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 9.2 °29, about 10.0 °29, and about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 9.2 °29, about 10.0 °29, and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 9.2 °29, about 10.0 °29, about 16.3 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 10.0 °29, about 16.3 °29, about 17.5 °29, and about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 9.2 °29, about 16.3 °29, about 17.5 °29, and about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 9.2 °29, about 10.0 °29, about 17.5 °29, and about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form II can be characterized by XRPD peaks at about 9.2 °29, about 10.0 °29, about 16.3 °29, and about 18.1 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by XRPD peaks at about 9.2 °29, about 10.0 °29, about 16.3 °29, and about 17.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by one or more XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °20, about 14.1 °20, about 15.7 °20, about 16.9 °20, about 19.1 °20, about 19.6 °20, about 21.1 °20, about 21.9 °20, about 22.4 °20, and about 25.8 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °20, about 14.1 °20, about 15.7 °20, about 16.9 °20, about 19.1 °20, about 19.6 °20, about 21.1 °20, about 2
  • Form II can be characterized by one XRPD peak selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °20, about 22.4 °20, and about 25.8 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • XRPD peak selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °20
  • Form II can be characterized by two XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °20, about 15.7 °20, about 16.9 °20, about 19.1 °20, about 19.6 °20, about 21.1 °20, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • two XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °20, about 15.7 °20, about 16.9 °20, about 19.1 °20, about 19.6 °20, about 21.1 °20, about 21.9
  • Form II can be characterized by three XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by four XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9
  • Form II can be characterized by five XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by six XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °20, about 16.9 °20, about 19.1 °20, about 19.6 °20, about 21.1 °20, about 21.9 °20, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • six XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °20, about 16.9 °20, about 19.1 °20, about 19.6 °20, about 21.1 °20, about 21.9
  • Form II can be characterized by seven XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °20, about 16.9 °20, about 19.1 °20, about 19.6 °20, about 21.1 °20, about 21.9 °20, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °20, about 16.9 °20, about 19.1 °20, about 19.6 °20, about 21.1 °20, about 21.9
  • Form II can be characterized by eight XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9
  • Form II can be characterized by nine XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • nine XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9
  • Form II can be characterized by ten XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • ten XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about
  • Form II can be characterized by eleven XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • eleven XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9
  • Form II can be characterized by twelve XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • twelve XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29about 19.6 °29, about 21.1 °29, about 21.9 °
  • Form II can be characterized by thirteen XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form II can be characterized by fourteen XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • fourteen XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9
  • Form II can be characterized by fifteen XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9 °29, about 22.4 °29, and about 25.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • XRPD peaks selected from about 17.5 °29, about 9.2 °29, about 10.0 °29, about 16.3 °29, about 18.1 °29, about 12.5 °29, about 14.1 °29, about 15.7 °29, about 16.9 °29, about 19.1 °29, about 19.6 °29, about 21.1 °29, about 21.9
  • Form II can have one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more, peaks as those listed in Table 2.
  • Table 2 Representative XRPD Peaks for Form II
  • FIG. 2B is a TG/DT plot of a sample of Form II.
  • TG showed a weight loss of about 11% up to about 85°C, and a further weight loss of 2.4 % up to about 325°C.
  • a potential endothermic event can be seen in the DT trace with a peak at about 212 °C.
  • Form II is characterized by a weight loss of about 11% between about 25 °C and about 85 °C.
  • Form II is characterized by an endothermic event, as measured by DT, with a peak at about 212 °C.
  • weight loss is determined by thermogravimetric analysis.
  • thermogravimetric analysis is conducted substantially as shown in Example 1.
  • endothermic events are calculated by differential thermal analysis.
  • differential thermal analysis is conducted substantially as shown in Example 1.
  • thermogravimetric analysis and differential thermal analysis are conducted simultaneously.
  • FIG. 2C shows PLM images of Form II, recovered from di chloromethane.
  • PLM indicated the material to be birefringent with irregular, needle-like morphology.
  • Form II is characterized by birefringent material with irregular, needle-like morphology.
  • Form III of Compound A can be prepared by crystallization from a number of solvents. For instance, Form III was recovered from acetonitrile by temperature cycling between ambient (about 22°C) and 40°C in 4 hour cycles for 72 hours. An XRPD spectrum of Form III, recovered from acetonitrile is shown in FIG. 3 A, obtained using Cu Ka radiation.
  • this application provides a method of making Form III of Compound A as disclosed herein, comprising recrystallizing Compound A from a solvent.
  • the solvent is acetonitrile.
  • Form III can be characterized by the XRPD peaks shown in FIG. 3A.
  • Form III can be characterized by an XRPD peak at about 10.7 °29 (e.g. 10.7 ⁇ 0.2 °29, 10.7 ⁇ 0.1 °29, 10.7 ⁇ 0.0 °20).
  • Form III can be further characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, and/or about 18.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be further characterized by XRPD peaks at about 15.0 °29, and/or about 17.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form III can be further characterized by XRPD peaks at about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and/or about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29 and about 10.7 °20 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form III can be characterized by XRPD peaks at about 11.2 °20 and about 10.7 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 16.5 °29 and about 10.7 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form III can be characterized by XRPD peaks at about 18.2 °29 and about 10.7 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, and about 10.7 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 16.5 °29, and about 11.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form III can be characterized by XRPD peaks at about 18.2 °29, about 16.5 °29, and about 11.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 18.2 °29, about 8.8 °29, and about 11.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form III can be characterized by XRPD peaks at about 18.2 °29, about 8.8 °29, and about 16.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 10.7 °29, about 16.5 °29, and about 11.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form III can be characterized by XRPD peaks at about 10.7 °29, about 8.8 °29, and about 11.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 10.7 °29, about 8.8 °29, and about 16.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form III can be characterized by XRPD peaks at about 10.7 °29, about 18.2 °29, and about 11.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 10.7 °29, about 18.2 °29, about 16.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form III can be characterized by XRPD peaks at about 10.7 °29, about 18.2 °29, and about 8.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 18.2 °29, about 8.8 °29, about 16.5 °29, and about 11.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form III can be characterized by XRPD peaks at about 10.7 °29, about 8.8 °29, about 16.5 °29, and about 11.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 10.7 °29, about 18.2 °29, about 16.5 °29, and about 11.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form III can be characterized by XRPD peaks at about 10.7 °29, about 18.2 °29, about 8.8 °29, and about 11.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 10.7 °29, about 18.2 °20, about 8.8 °20, and about 16.5 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, and about 15.0 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, and about 17.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, and about 15.0 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, and about 12.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, and about 12.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °20, about 15.0 °20, and about 16.1 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, and about 18.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, and about 19.0 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °20, about 15.0 °20, and about 19.6 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form III can be characterized by XRPD peaks at about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by one or more XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by one XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by two XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by three XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by four XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by five XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by six XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by seven XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by eight XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by nine XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by ten XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by eleven XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • eleven XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °
  • Form III can be characterized by twelve XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can be characterized by thirteen XRPD peaks selected from about 8.8 °29, about 11.2 °29, about 16.5 °29, about 18.2 °29, about 10.7 °29, about 17.8 °29, about 15.0 °29, about 12.2 °29, about 12.8 °29, about 16.1 °29, about 18.6 °29, about 19.0 °29, and about 19.6 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form III can have one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or more, peaks as those listed in Table 3.
  • FIG. 3B is a TG/DT plot of a sample of Form III.
  • TG showed a weight loss of about 3.7% up to about 75°C, a further weight loss of 4.7% up to about 160°C and a final weight loss of 0.6% up to 350°C.
  • a small, broad endothermic event was noted in the DT with an onset of about 196°C with a peak at about 204°C.
  • Form III is characterized by a weight loss of about 3.7% between about 25 °C and about 75 °C.
  • Form III is further characterized by a weight loss of about 4.7% between about 75 °C and about 160 °C.
  • Form III is further characterized by a weight loss of about 0.6% between about 160 °C and about 350 °C. In some embodiments, Form III is characterized by an endothermic event, as measured by DT, with an onset of about 196 °C. In some embodiments, Form III is characterized by an endothermic event, as measured by DT, with a peak at about 204 °C. In some embodiments, Form III is characterized by an endothermic event, as measured by DT, with an onset of about 196 °C and a peak at about 204 °C. In some embodiments, weight loss is determined by thermogravimetric analysis. In some embodiments, thermogravimetric analysis is conducted substantially as shown in Example 1. In some embodiments, endothermic events are calculated by differential thermal analysis. In some embodiments, differential thermal analysis is conducted substantially as shown in Example 1. In some embodiments, thermogravimetric analysis and differential thermal analysis are conducted simultaneously.
  • FIG. 3C shows PLM images of Form III, recovered from acetonitrile.
  • PLM indicated the material to be birefringent with irregular, lath-like morphology.
  • Form III is characterized by birefringent material with irregular, lath-like morphology.
  • Form IV of Compound A can be prepared by crystallization from a number of conditions. For instance, Form IV was recovered from dichloromethane/methanol (25:75 v/v) upon anti-solvent addition of tert-butyl methyl ether, and from dichloromethane/methanol (25:75 v/v) upon crash-cooling at 2-8 °C. An XRPD spectrum of Form IV, recovered from dichloromethane/methanol (25:75) after crash cooling is shown in FIG. 4A, obtained using Cu Ka radiation.
  • this application provides a method of making Form IV of Compound A as disclosed herein, comprising crash-cooling Compound A from a solvent.
  • the solvent is a mixture of dichloromethane and methanol.
  • the present disclosure provides a method of making the Form IV polymorph of Compound A, comprising addition of an anti-solvent to a solution of Compound A from a solvent.
  • the solvent comprises a mixture of di chloromethane and methanol.
  • the anti-solvent is tert-butyl methyl ether.
  • Form IV can be characterized by the XRPD peaks shown in FIG. 4 A.
  • Form IV can be characterized by an XRPD peak at about 10.5 °29 (e.g. 10.5 ⁇ 0.2 °29, 10.5 ⁇ 0.1 °29, 10.5 ⁇ 0.0 °20).
  • Form IV can be further characterized by XRPD peaks at about 14.5 °29, and/or about 16.9 °20 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be further characterized by XRPD peaks at about 11.5 °29, about 14.2 °29, and/or about 16.3 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). [0106] In some embodiments, Form IV can be characterized by XRPD peaks at about 14.5 °29 and about 10.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by XRPD peaks at about 16.9 °29 and about 10.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form IV can be characterized by XRPD peaks at about 14.5 °29, about 16.9 °29, and about 10.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by XRPD peaks at about 14.5 °29, about 16.9 °29, about 10.5 °29, and about 11.5 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form IV can be characterized by XRPD peaks at about 14.5 °29, about 16.9 °29, about 10.5 °29, and about 14.2 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by XRPD peaks at about 14.5 °29, about 16.9 °29, about 10.5 °29, and about 16.3 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation). In some embodiments, Form IV can be characterized by XRPD peaks at about 14.5 °29, about 16.9 °29, about 10.5 °29, about 11.5 °29, about 14.2 °29, and about 16.3 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by one or more XRPD peaks selected from at about 14.5 °29, about 16.9 °29, about 10.5 °29, about 11.5 °29, about 14.2 °29, about 16.3 °29, and about 17.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by one XRPD peak selected from at about 14.5 °29, about 16.9 °29, about 10.5 °29, about 11.5 °29, about 14.2 °29, about 16.3 °29, and about 17.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by two XRPD peaks selected from at about 14.5 °29, about 16.9 °29, about 10.5 °29, about 11.5 °29, about 14.2 °29, about 16.3 °29, and about 17.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by three XRPD peaks selected from at about 14.5 °29, about 16.9 °29, about 10.5 °29, about 11.5 °29, about 14.2 °29, about 16.3 °29, and about 17.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by four XRPD peaks selected from at about 14.5 °29, about 16.9 °29, about 10.5 °29, about 11.5 °29, about 14.2 °29, about 16.3 °29, and about 17.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by five XRPD peaks selected from at about 14.5 °29, about 16.9 °29, about 10.5 °29, about 11.5 °29, about 14.2 °29, about 16.3 °29, and about 17.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by six XRPD peaks selected from at about 14.5 °29, about 16.9 °29, about 10.5 °29, about 11.5 °29, about 14.2 °29, about 16.3 °29, and about 17.8 °29 (e.g., ⁇ 0.2 °29, ⁇ 0.1 °29, or ⁇ 0.0 °29; Cu Ka radiation).
  • Form IV can be characterized by seven XRPD peaks selected from at about 14.5 °29, about 16.9 °29, about 10.5 °29, about 11.5 °29, about 14.2 °29, about 16.3 °29, and about 17.8 °20 (e.g., ⁇ 0.2 °20, ⁇ 0.1 °20, or ⁇ 0.0 °20; Cu Ka radiation).
  • Form IV can have one, two, three, four, five, six, seven, or more, peaks as those listed in Table 4.
  • FIG. 4B is a TG/DT plot of a sample of Form IV.
  • TG showed a weight loss of about 3.1% up to about 350°C.
  • a small, broad endothermic event was noted in the DT with an onset of about 196°C with a peak at about 213°C.
  • Form IV is characterized by a weight loss of about 3.1% between about 25 °C and about 350 °C.
  • Form IV is characterized by an endothermic event, as measured by DT, with an onset of about 196 °C.
  • Form IV is characterized by an endothermic event, as measured by DT, with a peak at about 213 °C.
  • Form IV is characterized by an endothermic event, as measured by DT, with an onset of about 196 °C and a peak at about 213 °C.
  • weight loss is determined by thermogravimetric analysis.
  • thermogravimetric analysis is conducted substantially as shown in Example 1.
  • endothermic events are calculated by differential thermal analysis.
  • differential thermal analysis is conducted substantially as shown in Example 1.
  • thermogravimetric analysis and differential thermal analysis are conducted simultaneously.
  • FIG. 4C shows PLM images of Form IV, recovered from dichloromethane:methanol (25:75 v/v).
  • PLM indicated the material to be birefringent with irregular, lath-like morphology.
  • Form III is characterized by birefringent material with irregular, lath-like morphology.
  • a polymorph of the invention may be used in various ways.
  • a polymorph of Compound A serves as a convenient storage (e.g., bulk storage) form useful for the preparation of an amorphous form of Compound A.
  • a polymorph of Compound A may be further used in the preparation of pharmaceutical compositions of the disclosure or final dosage form, including, for example, tablets or capsules.
  • the amorphous form of Compound A may be further used in the preparation of pharmaceutical compositions of the disclosure or final dosage form, including, for example, tablets or capsules.
  • the bulk storage form of Compound A is substantially the polymorph of Form I.
  • the bulk storage form of Compound A is substantially the polymorph of Form II.
  • the bulk storage form of Compound A is substantially the polymorph of Form III.
  • the bulk storage form of Compound A is substantially the polymorph of Form IV.
  • This application further provides an amorphous form of Compound A.
  • the bulk storage form of Compound A is substantially the amorphous form of Compound A.
  • the amorphous form of Compound A prepared as described herein is used in the preparation of one or more pharmaceutical compositions or dosage forms of the invention, e.g., tablets or capsules, comprising Compound A
  • This application further provides pharmaceutical compositions comprising a therapeutically effective amount of at least one crystalline and/or amorphous form of Compound A as described herein, in combination with a dispersing agent, carrier, additive or other pharmaceutical excipient, or a combination thereof.
  • the application further provides pharmaceutical compositions comprising a therapeutically effective amount of an amorphous form of Compound A as described herein, in combination with a dispersing agent, carrier, additive or other pharmaceutical excipient, or a combination thereof.
  • the dispersing agent is hydroxypropyl methylcellulose (HPMC).
  • the additive is D-a-tocopheryl polyethylene glycol succinate (Vitamin E TPGS or TPGS).
  • Compound A whether substantially in a crystalline form or amorphous form of the invention as described herein may, in accordance with the disclosure, be administered in a pharmaceutical composition to a patient or subject in single or divided doses.
  • the pharmaceutical composition may be administered orally, parenterally, by inhalation, topically, rectally, nasally, buccally, vaginally, transdermally, sublingually, via suppository administration, or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intra-sternal, intra-thecal, intra-hepatic, intra-lesional and intra-cranial injection or by infusion.
  • the pharmaceutical composition is administered orally.
  • Enteric coated oral tablets may be used to enhance bioavailability of the compounds from an oral route of administration.
  • the most effective dosage form will depend upon the pharmacokinetics of the particular crystalline and/or amorphous form chosen, as well as the severity of the disease and/or condition being treated in the patient.
  • Administration of Compound A according to the present disclosure as a spray, mist, or aerosol for intra-nasal, intra-tracheal, intraocular, or pulmonary administration may be used.
  • the present disclosure therefore also is directed to pharmaceutical compositions comprising a therapeutically effective amount of a crystalline form and/or amorphous form of Compound A, or combination thereof as described herein, in combination with a pharmaceutically acceptable carrier, additive or excipient.
  • Compound A may be administered in immediate release, sustained release, or controlled release forms. Sustained or controlled release forms are preferably administered orally, but may alternatively be administered in suppository, transdermal or other topical form. Intramuscular injections, e.g., in liposomal form, may be used to control (e.g., sustain) the release of Compound A at an injection site.
  • compositions described herein may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers, and may be administered in controlled-release formulations.
  • Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • Sterile injectable forms of the pharmaceutical compositions described herein may be aqueous or oleaginous suspensions. These suspensions may be formulated according to techniques known in the art in view of this disclosure using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable form may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3 -butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution, among others.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides, among others.
  • Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.
  • the pharmaceutical compositions described herein may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers which are commonly used include lactose and corn starch, among others.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch, among others.
  • the active ingredient may be combined with one or more emulsifying and suspending agents. If desired, certain buffering, sweetening, flavoring and/or coloring agents may also be added.
  • compositions described herein may be administered in the form of a suppository or enema for rectal administration, either for local administration to the lower intestinal tract, or for systemic absorption and treatment.
  • a suppositories can be prepared, in view of this disclosure, by mixing Compound A, either in a substantially crystalline form or substantially amorphous form, with a suitable non-irritating excipient, which is solid or semi-solid at room temperature but liquid at rectal temperature, thereby melting in the rectum to release the drug.
  • excipients may include cocoa butter, beeswax, polyethylene glycols, and combinations thereof.
  • compositions described herein may alternatively be administered topically.
  • the present invention provides a pharmaceutical formulation comprising Compound A in a crystalline form such as Form I, Form II, Form III or Form IV, or in amorphous form, and adapted for topical application such as, e.g., as a salve, ointment, lotion, emulsion or topical liquid.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component (i.e., Compound A) suspended or dissolved in one or more carriers.
  • Carriers for topical administration include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical formulation of the invention may be delivered via a transdermal patch to be worn for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days.
  • the transdermal patch would be a reservoir patch.
  • the transdermal patch would be a drug-in-adhesive patch.
  • a transdermal patch according to the invention may also comprise one or more absorption enhancers.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • compositions as described herein may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques known in the art of pharmaceutical formulation in view of this disclosure and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • the amount of compound in a pharmaceutical composition of the invention may be combined with the carrier or excipient materials to produce single dosage forms, which will vary depending upon the host and disease treated, as well as the particular mode of administration.
  • the single dosage form will be formulated to contain between about 0.05 milligram and about 750 milligrams, more preferably about 1 milligram to about 600 milligrams, and even more preferably about 10 milligrams to about 500 milligrams of active ingredient, alone or in combination with at least one other therapeutically active compound.
  • the other therapeutically active compound is an anti-cancer agent.
  • the polymorph (crystalline form) and/or amorphous form of Compound A, or a pharmaceutical composition thereof is conveniently administered in any suitable unit dosage form, including but not limited to one containing less than 1 mg, 1 mg to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form.
  • An oral dosage of about 25-250 mg may be a convenient dosage.
  • a patient or subject in need of therapy using a pharmaceutical composition according to the methods described herein can be treated by administering to the patient (subject) a therapeutically effective amount of the composition thereof.
  • the active compound is included in the pharmaceutical composition in an amount sufficient to deliver to a patient a therapeutically effective amount for the desired indication, without causing undue adverse effects in the patient treated.
  • a dose of the active compound for all of the herein-mentioned conditions is in the range from about 10 ng/kg to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient/patient per day.
  • the active ingredient is preferably administered to achieve peak plasma concentrations of the active compound of about 0.00001-30 mM, preferably about 0.1-30 pM. This may be achieved, for example, by oral administration of a tablet or capsule, or by the intravenous injection of a solution or formulation of the active ingredient.
  • the concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered all at once, or may be divided into a number of smaller doses to be administered at selected intervals of time.
  • Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or com starch; a buffer; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or com starch
  • a buffer such as stearate
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such as suc
  • dosage unit form When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil.
  • dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
  • the active polymorph and/or amorphous form of Compound A or a composition thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
  • a syrup may contain, in addition to the active compounds, a sweetening agent such as sucrose and certain preservatives, dyes and colorings and flavors.
  • the active polymorph and/or amorphous form of Compound A or a composition thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as another anti-cancer agents, among others.
  • one or more compounds, polymorphs, and/or amorphous forms according to the present disclosure are co-administered with another bioactive agent, such as another anticancer agent or a wound healing agent.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • carriers can include physiological saline or phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • the active compound, polymorph, and/or amorphous forms are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the description provides therapeutic compositions comprising a therapeutically effective amount of a polymorph and/or amorphous form of Compound A, or a pharmaceutical composition thereof as described herein, and a pharmaceutically acceptable carrier.
  • the therapeutic compositions of the invention modulate protein degradation in a patient or subject, for example, an animal such as a human, and can be used for treating or ameliorating disease states or conditions which are causally related to the protein to be degraded.
  • treat refers to any action providing a benefit to a patient for which the active compound, polymorph, and/or amorphous forms may be administered, including the treatment of any disease state or condition, which is causally related (e.g. modulated) to the ER including one or more symptoms thereof.
  • Disease states or conditions including breast cancer, uterine cancer, ovarian cancer, and/or endometriosis, which may be treated using compounds, polymorphs, amorphous forms and/or pharmaceutical compositions according to the present disclosure are set forth hereinabove.
  • the description provides therapeutic pharmaceutical compositions as described herein for effectuating the degradation of the ER for the treatment or amelioration of a disease, e.g., cancer.
  • a disease e.g., cancer.
  • the disease is breast cancer, uterine cancer, ovarian cancer, endometrial cancer, or endometriosis.
  • the description provides a method of ubiquitinating/ degrading the ER in a cell.
  • the method comprises administering the bifunctional compound, Compound A, as described herein or a polymorph and/or amorphous form thereof, such that ubiquitination of the ER will occur when placed in proximity to the ubiquitin ligase, leading to ubiquitination and subsequent degradation of the target protein via the proteasomal pathway, providing the control (i.e., reduction) of ER protein levels.
  • the control of ER levels afforded by the invention of the present disclosure provides treatment of a disease state, condition, or symptom causally related to the ER by lowering the level of ER in cells of the patient.
  • the method comprises administering a therapeutically effective amount of Compound A as described herein, optionally including one or more pharmaceutically acceptable excipients (e.g., dispersing agent, carrier, lubricant), optionally including another bioactive agent, and combinations thereof.
  • pharmaceutically acceptable excipients e.g., dispersing agent, carrier, lubricant
  • the description provides methods for treating or ameliorating a disease, disorder or symptom thereof in a subject or a patient, e.g., an animal such as a human, comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount, e.g., a therapeutically effective amount, of Compound A as described herein and a pharmaceutically acceptable excipient (e.g., dispersing agent, carrier, lubricant), other bioactive agent, or combination thereof, wherein the composition is effective for treating or ameliorating the disease or disorder or a symptom thereof, in the subject.
  • a pharmaceutically acceptable excipient e.g., dispersing agent, carrier, lubricant
  • the present disclosure is directed to a method of treating a human patient in need thereof for a disease state, condition or symptom causally related to the ER protein where the degradation of the ER protein produces a therapeutic effect in the patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of Compound A according to the present disclosure, optionally in combination with another bioactive agent.
  • the disease state, condition or symptom may be caused by expression or overexpression of the ER protein.
  • disease state, condition or symptom is used to describe any disease state, condition or symptom causally related to protein activity, overactivity, expression or overexpression (e.g., the amount of ER expressed in a patient is elevated) where targeted degradation of the protein in a patient provides a beneficial therapy or relief of the disease state, condition or symptom to the patient.
  • the disease state or condition may be reduced, mitigated or ameliorated.
  • the disease state, condition or symptom may be reversed or cured.
  • neoplasia and “cancer”, as used in the specification, refer to the pathological process that results in the formation and growth of a cancerous or malignant neoplasm, i.e., abnormal tissue that grows by cellular proliferation, often more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease.
  • malignant neoplasms show partial or complete lack of structural organization and functional coordination with the normal tissue and most invade surrounding tissues, metastasize to several sites, and are likely to recur after attempted removal and to cause the death of the patient unless adequately treated.
  • neoplasia is used to describe any and all cancerous disease states and embraces or encompasses the pathological process associated with malignant hematogenous, ascitic and solid tumors.
  • Exemplary cancers which may be treated by the present compound polymorphs, and/or amorphous forms either alone or in combination with at least one additional anti-cancer agent include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, endometrial, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sar
  • Additional cancers which may be treated using compounds according to the present disclosure include, for example, T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML.
  • the cancers which may be treated by the present compound, polymorphs, and/or amorphous forms either alone or in combination with at least one additional anti-cancer agent include breast cancer, ovarian cancer, endometrial cancer or uterine cancer.
  • the present disclosure also provides methods for the control (e.g. reduction) of protein levels within a cell. This is based on the use of Compound A, or a polymorph or amorphous form thereof, as described herein, which results in the targeted ubiquitination of the ER protein and its proteasomal degradation resulting in the control (i.e. reduction) of the amount of the ER protein in cells of a biological system or subject or patient, e.g. to gain a particular therapeutic benefit.
  • Embodiment 1 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l,2,3,4- tetrahydronaphthal en- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 13.9 °29 and about 17.9 °29 using Cu Ka radiation.
  • Embodiment 2 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l, 2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 13.9 °29, about 16.4 °29, and about 17.9 °29 using Cu Ka radiation.
  • Embodiment 3 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l, 2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A)
  • Compound A characterized by an X-ray powder diffraction pattern including peaks at about 13.9 °29, about 16.2 °29, and about 17.9 °29 using Cu Ka radiation.
  • Embodiment 4 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l, 2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 13.9 °29, about 17.9 °29, and about 20.9 °29 using Cu Ka radiation.
  • Embodiment 5 A polymorph (designated as Form I) of (S)-3-(5-(4-((l-(4-((lR,2S)-6- hydroxy-2-phenyl- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- l-oxoisoindolin-2-yl)piperidine-2, 6-dione (Compound A)
  • Compound A characterized by an X-ray powder diffraction pattern including peaks at about 13.9 °29 and about 17.9 °29 using Cu Ka radiation.
  • Embodiment 6 The polymorph of embodiment 1, further characterized by an X-ray powder diffraction pattern including a peak at about 16.4 °29, using Cu Ka radiation.
  • Embodiment 7 The polymorph of embodiment 1, further characterized by an X-ray powder diffraction pattern including at least one peak selected from about 16.2 °29, about 16.4 °29, about 18.5 °29, and about 29.9 °29, using Cu Ka radiation.
  • Embodiment 8 The polymorph of embodiment 1, further characterized by an X-ray powder diffraction pattern including peaks at about 16.2 °29, about 16.4 °29, about 18.5 °29, and about 29.9 °29, using Cu Ka radiation.
  • Embodiment 9 The polymorph of any one of embodiments 1-8, further characterized by an X-ray powder diffraction pattern including at least one peak selected from about 13.5 °29, about 14.3 °29, about 14.5 °29, about 16.8 °29, using Cu Ka radiation.
  • Embodiment 10 The polymorph of any one of embodiments 1-9, further characterized by an X-ray powder diffraction pattern including peaks at about 13.5 °29, about 14.3 °29, about 14.5 °29, about 16.8 °29, using Cu Ka radiation.
  • Embodiment 11 The polymorph of any one of embodiments 1-10, characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 1 A.
  • Embodiment 12. The polymorph of any one of embodiments 1-11, further characterized by an endothermic event, as measured by DT, having an onset of about 259 °C and a peak at about 266
  • Embodiment 13 The polymorph of any one of embodiments 1-12, further characterized by a weight loss, as measured by TG, of about 1% between about 25 °C and about 250°C.
  • Embodiment 14 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l, 2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 10.0 °29 and about 17.5 °29 using Cu Ka radiation.
  • Embodiment 15 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l, 2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 10.0 °29, about 16.3 °29, and about 17.5 °29 using Cu Ka radiation.
  • Embodiment 16 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l,2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 9.2 °29, about 16.3 °29, and about 17.5 °29 using Cu Ka radiation.
  • Embodiment 17 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l, 2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 16.3 °29, about 17.5 °29, and about 18.1 °29 using Cu Ka radiation. Embodiment 18.
  • Embodiment 19 The polymorph of embodiment 14 or 18, further characterized by an X-ray powder diffraction pattern including a peak at about 16.3 °29, using Cu Ka radiation.
  • Embodiment 20 The polymorph of any one of embodiments 14-19, further characterized by an X-ray powder diffraction pattern including at least one peak selected from at about 9.2 °29, about 16.3 °29, and about 18.1 °29, using Cu Ka radiation.
  • Embodiment 21 The polymorph of any one of embodiments 14-20, further characterized by an X-ray powder diffraction pattern including peaks at about 9.2 °29, about 16.3 °29, and about 18.1 °29, using Cu Ka radiation.
  • Embodiment 22 The polymorph of any one of embodiments 14-21, characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 2A.
  • Embodiment 23 The polymorph of any one of embodiments 14-22, further characterized by an endothermic event, as measured by DT, with a peak at about 212 °C.
  • Embodiment 24 The polymorph of any one of embodiments 14-23, further characterized by a weight loss, as measured by TG, of about 11% between about 25 °C and about 85 °C.
  • Embodiment 25 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l, 2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 10.7 °29 and 18.2 °29 using Cu Ka radiation.
  • Embodiment 26 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l,2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 8.8 °29, about 10.7 °29, and about 18.2 °29 using Cu Ka radiation.
  • Embodiment 27 Compound A
  • Embodiment 28 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l,2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 10.7 °29, about 16.5 °29, and about 18.2 °29 using Cu Ka radiation.
  • Embodiment 29 A polymorph (designated as Form III) of (S)-3-(5-(4-((l-(4-((lR,2S)-6- hydroxy-2-phenyl- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- l-oxoisoindolin-2-yl)piperidine-2, 6-dione (Compound A)
  • Compound A characterized by an X-ray powder diffraction pattern including peaks at about 10.7 °29 and 18.2 °29 using Cu Ka radiation.
  • Embodiment 30 The polymorph of any one of embodiments 25 or 27-29, further characterized by an X-ray powder diffraction pattern including a peak at about 8.8 °29, using Cu Ka radiation.
  • Embodiment 31 The polymorph of any one of embodiments 25-30, further characterized by an X-ray powder diffraction pattern including at least one peak selected from about 8.8 °29, about 11.2 °29, about 15.0 °29, about 16.5 °29, and about 17.8 °29, using Cu Ka radiation.
  • Embodiment 32 The polymorph of any one of embodiments 25-31, further characterized by an X-ray powder diffraction pattern including peaks at about 8.8 °29, about 11.2 °29, about 15.0 °29, about 16.5 °29, and about 17.8 °29, using Cu Ka radiation.
  • Embodiment 33 The polymorph of any one of embodiments 25-32, further characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 3 A.
  • Embodiment 34 The polymorph of any one of embodiments 25-33, further characterized by an endothermic event, as measured by DT, with an onset of about 196 °C and a peak at about 294
  • Embodiment 35 The polymorph of any one of embodiments 25-34, further characterized by a weight loss, as measured by TG, of about 3.7% between about 25 °C and about 75 °C.
  • Embodiment 36 The polymorph of embodiment 35, further characterized by a weight loss, as measured by TG, of about 4.7% between about 75 °C and about 160 °C.
  • Embodiment 37 The polymorph of embodiment 36, further characterized by a weight loss, as measured by TG, of about 0.6% between about 160 °C and about 350 °C.
  • Embodiment 38 A polymorph of (S)-3-(5-(4-((l-(4-((lR,2S)-6-hydroxy-2-phenyl-l, 2,3,4- tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin-2- yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 10.5 °29, about 14.5 °29, and about 16.9 °29.
  • Embodiment 39 A polymorph (designated as Form IV) of (S)-3-(5-(4-((l-(4-((lR,2S)-6- hydroxy-2-phenyl- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)phenyl)piperidin-4-yl)methyl)piperazin- 1 -yl)- l-oxoisoindolin-2-yl)piperidine-2, 6-dione (Compound A) (Compound A) characterized by an X-ray powder diffraction pattern including peaks at about 10.5 °29, about 14.5 °29, and about 16.9 °29.
  • Embodiment 40 Compound A
  • the polymorph of embodiment 38 or 39 further characterized by an X-ray powder diffraction pattern including at least one peak selected from about 11.5 °29, about 14.2 °29, about 16.3 °29, and about 17.8 °29, using Cu Ka radiation.
  • Embodiment 41 The polymorph of any one of embodiments 38-40, further characterized by an X-ray powder diffraction pattern including peaks at about 11.5 °29, about 14.2 °29, about 16.3 °29, and about 17.8 °29, using Cu Ka radiation.
  • Embodiment 42 The polymorph of any one of embodiments 38-41, characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 4A.
  • Embodiment 43 The polymorph of any one of embodiments 38-42, further characterized by an endothermic event, as measured by DT, with an onset of about 196 °C and a peak at about 213 °C.
  • Embodiment 44 The polymorph of any one of embodiments 38-43, further characterized by a weight loss, as measured by TG, of about 3.1% between about 25 °C and about 359 °C.
  • Embodiment 45 A method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the polymorph of any one of embodiments 1-44.
  • Embodiment 46 The method of embodiment 45, wherein the disease or disorder is associated with estrogen receptor (ER) activity, overactivity, constitutive activity, expression, overexpression, or accumulation and aggregation.
  • ER estrogen receptor
  • Embodiment 47 The method of embodiment 45 or 46, wherein the disease or disorder is cancer or a neoplasia associated with ER activity, overactivity, constitutive activity, expression, overexpression, or accumulation and aggregation .
  • Embodiment 48 The method of any one of embodiments 45-47, wherein the disease or disorder is breast cancer or uterine cancer or endometriosis.
  • Embodiment 49 A pharmaceutical composition comprising a therapeutically effective amount of the polymorph of any one of embodiments 1-44 and a pharmaceutically acceptable carrier wherein the composition is effective in treating or ameliorating at least one symptom of the disease or disorder.
  • Embodiment 50 The composition according to embodiment 49, wherein the disease or disorder is associated with overactivity, constitutive activity, or ER accumulation and aggregation.
  • Embodiment 51 The composition according to embodiment 49 or 50, wherein the disease or disorder is cancer or a neoplasia associated with ER accumulation and aggregation, or ER activity or over-activity.
  • Embodiment 52 The composition according to any one of embodiments 49-51, wherein the disease or disorder is breast cancer or uterine cancer or endometriosis.
  • Embodiment 53 A pharmaceutical composition comprising a therapeutically effective amount of an amorphous form of Compound A (Compound A) and a pharmaceutically acceptable dispersing agent.
  • Embodiment 54 The composition of embodiment 53 further comprising a pharmaceutically acceptable additive.
  • Embodiment 55 The composition of embodiment 53 or 54 wherein the pharmaceutically acceptable additive is HPMC.
  • Embodiment 56 The composition of embodiments 53 or 54 wherein the pharmaceutically acceptable additive is TPGS.
  • Embodiment 57 The composition of any one of embodiments 53-56 wherein the composition is effective in treating or ameliorating at least one symptom of the disease or disorder.
  • Embodiment 58 The composition according to embodiment 57, wherein the disease or disorder is associated with overactivity, constitutive activity, or ER accumulation and aggregation.
  • Embodiment 59 The composition according to embodiment 57 or 58, wherein the disease or disorder is cancer or a neoplasia associated with ER accumulation and aggregation, or ER activity or over-activity.
  • Embodiment 60 The composition according to any one of embodiments 57-59, wherein the disease or disorder is breast cancer or uterine cancer or endometriosis.
  • Embodiment 61 Use of the polymorph of any one of embodiments 1-44 in the manufacture of a medicament for the treatment of a disease or disorder.
  • Embodiment 62 The use according to embodiment 61, wherein the disease or disorder is associated with ER accumulation and aggregation, or ER activity or over-activity.
  • Embodiment 63 The use according to embodiment 61 or 62, wherein the disease or disorder is cancer or a neoplasia associated with ER accumulation and aggregation, or ER activity or overactivity.
  • Embodiment 64 The use according to any one of embodiments 61-63, wherein the disease or disorder is breast cancer or uterine cancer, or endometriosis.
  • Embodiment 65 The polymorph of any one of embodiments 1-44 for use in medicine.
  • Embodiment 66 The polymorph of any one of embodiments 1-44 for use in the treatment of a disease or disorder, wherein the disease or disorder is associated with ER accumulation and aggregation, or ER activity or over-activity.
  • Embodiment 67 The polymorph for use according to embodiment 66, wherein the disease or disorder is cancer or a neoplasia associated with ER accumulation and aggregation, or ER activity or over-activity.
  • Embodiment 68 The polymorph for use according to embodiment 66 or 67, wherein the disease or disorder is breast cancer or uterine cancer, or endometriosis.
  • Embodiment 69 A method of making the polymorph of Compound A of any one of embodiments 1-13, comprising recrystallizing Compound A from a solvent.
  • Embodiment 70 The method of embodiment 69, wherein the solvent is selected from the group consisting of acetone, 1 -butanol, 2-ethoxy ethanol, ethanol, ethyl acetate, isopropyl acetate, methanol, methyl ethyl ketone, 1 -propanol, 2-propanol, polyethylene glycol, and a mixture of ethanol/water.
  • the solvent is selected from the group consisting of acetone, 1 -butanol, 2-ethoxy ethanol, ethanol, ethyl acetate, isopropyl acetate, methanol, methyl ethyl ketone, 1 -propanol, 2-propanol, polyethylene glycol, and a mixture of ethanol/water.
  • Embodiment 71 The method of embodiment 69, wherein the solvent is 1-butanol.
  • Embodiment 72 The method of embodiment 69, wherein the solvent is methyl ethyl ketone
  • Embodiment 73 A method of making the polymorph of Compound A of any one of embodiments 14-24, comprising recrystallizing Compound A from a solvent.
  • Embodiment 74 The method of embodiment 73, wherein the solvent is selected from dichloromethane and a mixture of acetone/water.
  • Embodiment 75 A method of making the polymorph of Compound A of any one of embodiments 25-37, comprising recrystallizing Compound A from a solvent.
  • Embodiment 76 The method of embodiment 75, wherein the solvent is acetonitrile.
  • Embodiment 77 A method of making the polymorph of Compound A of any one of embodiments 38-44, comprising crash-cooling a solution of Compound A in a solvent.
  • Embodiment 78 A method of making the polymorph of Compound A of any one of embodiments 38-44, comprising addition of an anti-solvent to a solution of Compound A in a solvent.
  • Embodiment 79 The method of embodiment 77 or 78, wherein the solvent is a mixture of di chloromethane and methanol.
  • Embodiment 80 The method of embodiment 79, wherein the ratio of dichloromethane and methanol is about 25:75 (v/v).
  • Embodiment 81 The method of any one of embodiments 78-80, wherein the anti-solvent is tert-butyl methyl ether.
  • Compound A can be prepared according to the methods disclosed in LIS Patent No. 10,647,698, which is incorporated herein for all purposes. The following examples are used to assist in describing the present disclosure, but should not be seen as limiting the present disclosure in any way.
  • TGA Thermogravimetric Analysis
  • DTA Differential Thermal Analysis
  • Form I was found to be a thermodynamically stable, non-solvated form with a high melting point (259°C). This form possesses excellent stability, good solubility in process relevant solvents and improved solubility at lower biorelevant pH, as well as low hygroscopicity (1.7 wt.% at 90% RH). Of the four forms identified, Form I was determined to be the most stable. A summary of the relevant characteristics of Form I is found below in Table 10:
  • Amorphous or partially amorphous solid was slurried in PEG-400 and temperature cycled between RT and 40 °C overnight. The solids were isolated from the supernatant, washed first with ethanol and then methyl ethyl ketone, and dried in a vacuum oven to yield flat, plate-like crystals.
  • Form II appears to be a crystalline, kinetic form. It appears to be non-solvated and likely hydrated. It has very small particle size and acicular rod morphology.
  • Form III appears to be a crystalline, kinetic form. It possesses a high melting temperature after de-hydration (onset 196°C). It appears to be non-solvated and likely hydrated. It shows some loss of crystallinity on de-hydration.
  • amorphous Compound A free base was suspended in 1.0 mL dichloromethane:methanol (25:75 v/v). The experiment was temperature cycled between ambient temperature (ca. 22°C) and 40°C in 4-hour cycles for 72 hours. After 72 hours, the sample was filtered through a 0.22 pm nylon filter and the supernatant retained. The supernatant was cooled to between 2 and 8°C in a refrigerator and held for 72 hours. After 72 hours, the resulting solids were isolated by centrifuge filtration and analyzed as a damp powder.
  • Form IV was found to be partly crystalline.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/US2021/050046 2020-09-14 2021-09-13 Crystalline forms of a compound for the targeted degradation of estrogen receptor Ceased WO2022056368A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CR20230162A CR20230162A (es) 2020-09-14 2021-09-13 Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
MX2023002979A MX2023002979A (es) 2020-09-14 2021-09-13 Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos.
IL301155A IL301155A (en) 2020-09-14 2021-09-13 Crystalline forms of a compound for the targeted degradation of estrogen receptor
PE2023001149A PE20231555A1 (es) 2020-09-14 2021-09-13 Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos
CA3194954A CA3194954A1 (en) 2020-09-14 2021-09-13 Crystalline forms of a compound for the targeted degradation of estrogen receptor
AU2021342287A AU2021342287A1 (en) 2020-09-14 2021-09-13 Crystalline forms of a compound for the targeted degradation of estrogen receptor
CN202180070126.4A CN116390916A (zh) 2020-09-14 2021-09-13 用于靶向降解雌激素受体的化合物的结晶形式
EP21787193.8A EP4211128A1 (en) 2020-09-14 2021-09-13 Crystalline forms of a compound for the targeted degradation of estrogen receptor
JP2023516491A JP2023541434A (ja) 2020-09-14 2021-09-13 エストロゲン受容体の標的化分解のための化合物の結晶性形態
BR112023004656A BR112023004656A2 (pt) 2020-09-14 2021-09-13 Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
KR1020237011950A KR20230069144A (ko) 2020-09-14 2021-09-13 에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태
DO2023000052A DOP2023000052A (es) 2020-09-14 2023-03-14 Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
CONC2023/0004435A CO2023004435A2 (es) 2020-09-14 2023-04-10 Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063078225P 2020-09-14 2020-09-14
US63/078,225 2020-09-14

Publications (1)

Publication Number Publication Date
WO2022056368A1 true WO2022056368A1 (en) 2022-03-17

Family

ID=78080527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/050046 Ceased WO2022056368A1 (en) 2020-09-14 2021-09-13 Crystalline forms of a compound for the targeted degradation of estrogen receptor

Country Status (20)

Country Link
US (2) US12162859B2 (https=)
EP (1) EP4211128A1 (https=)
JP (1) JP2023541434A (https=)
KR (1) KR20230069144A (https=)
CN (1) CN116390916A (https=)
AR (1) AR123492A1 (https=)
AU (1) AU2021342287A1 (https=)
BR (1) BR112023004656A2 (https=)
CA (1) CA3194954A1 (https=)
CL (1) CL2023000712A1 (https=)
CO (1) CO2023004435A2 (https=)
CR (1) CR20230162A (https=)
DO (1) DOP2023000052A (https=)
EC (1) ECSP23027481A (https=)
IL (1) IL301155A (https=)
MX (1) MX2023002979A (https=)
PE (1) PE20231555A1 (https=)
RS (1) RS20230288A1 (https=)
TW (1) TW202214236A (https=)
WO (1) WO2022056368A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229286A (zh) * 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
US12162859B2 (en) 2020-09-14 2024-12-10 Arvinas Operations, Inc. Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
WO2024258856A1 (en) * 2023-06-12 2024-12-19 Arvinas Operations, Inc. Solid oral dosage forms of estrogen receptor degraders
US12172981B2 (en) 2016-12-01 2024-12-24 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2025245032A1 (en) 2024-05-20 2025-11-27 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
WO2026018182A1 (en) 2024-07-19 2026-01-22 Pfizer Inc. Process for preparing a cis-1,2-diaryltetralin derivative

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115397821B (zh) 2019-10-17 2024-09-03 阿尔维纳斯运营股份有限公司 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102725A1 (en) * 2016-12-01 2018-06-07 Arvinas, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
NZ333903A (en) 1996-07-24 2000-02-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
CA2287387C (en) 1997-05-14 2010-02-16 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
JP2001517664A (ja) 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー ベンゾチオフェン類
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
US6333344B1 (en) 1999-05-05 2001-12-25 Merck & Co. Prolines as antimicrobial agents
US7041298B2 (en) 2000-09-08 2006-05-09 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
CA2432932A1 (en) 2001-02-16 2002-08-29 Mark A. Scialdone Angiogenesis-inhibitory tripeptides, compositions and their methods of use
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7932382B2 (en) 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2005094818A1 (en) 2004-03-23 2005-10-13 Genentech, Inc. Azabicyclo-octane inhibitors of iap
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
BRPI0511350A (pt) 2004-07-02 2007-12-04 Genentech Inc composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
CN100383139C (zh) 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
WO2006113942A2 (en) 2005-04-20 2006-10-26 Schering Corporation Method of inhibiting cathepsin activity
KR20080042158A (ko) 2005-08-31 2008-05-14 셀진 코포레이션 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
BRPI0708524A2 (pt) 2006-03-03 2011-05-31 Novartis Ag compostos de n-formil hidroxilamina
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
US20070218138A1 (en) 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
JP5230610B2 (ja) 2006-05-05 2013-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
JP2009544620A (ja) 2006-07-20 2009-12-17 リガンド・ファーマシューティカルズ・インコーポレイテッド 自己免疫疾患及び炎症のためのプロリン尿素ｃｃｒ１アンタゴニスト
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
MX2009001989A (es) 2006-08-30 2009-03-09 Celgene Corp Compuestos de isoindolina 5-substituidos.
RU2448101C2 (ru) 2006-08-30 2012-04-20 Селджин Корпорейшн 5-замещенные изоиндолиновые соединения
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
WO2008109057A1 (en) 2007-03-02 2008-09-12 Dana-Farber Cancer Institute, Inc. Organic compounds and their uses
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
PE20130150A1 (es) 2007-04-30 2013-02-27 Genentech Inc Inhibidores de las iap
WO2008144925A1 (en) 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP5451602B2 (ja) 2007-06-08 2014-03-26 アッヴィ・インコーポレイテッド キナーゼ阻害薬としての５−ヘテロアリール置換インダゾール類
KR20100038108A (ko) 2007-07-25 2010-04-12 브리스톨-마이어스 스큅 컴퍼니 트리아진 키나제 억제제
ES2534899T3 (es) * 2007-08-06 2015-04-30 Janssen Pharmaceutica, N.V. Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
PE20110547A1 (es) 2008-10-29 2011-08-04 Celgene Corp Compuestos de isoindolina con actividad anticancerigena
JP5487214B2 (ja) 2008-12-19 2014-05-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
WO2010141805A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
JP2012532929A (ja) 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
SG186389A1 (en) 2010-06-30 2013-01-30 Univ Brandeis Small-molecule-targeted protein degradation
EP2619184B1 (en) 2010-09-24 2018-05-23 The Regents of the University of Michigan Deubiquitinase inhibitors and methods for use of the same
CN102477033A (zh) 2010-11-23 2012-05-30 苏州波锐生物医药科技有限公司 苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途
AU2011338615B2 (en) 2010-12-07 2017-07-27 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
US20140243282A1 (en) 2010-12-31 2014-08-28 Satish Reddy Kallam Methods and compositions for designing novel conjugate therapeutics
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
CA2834535A1 (en) 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
WO2013071035A1 (en) 2011-11-09 2013-05-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis
WO2013071039A1 (en) 2011-11-09 2013-05-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis
CN103159736B (zh) 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
US9273046B2 (en) 2011-12-31 2016-03-01 Beigene, Ltd. Fused tricyclic compounds as Raf kinase inhibitors
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US20150119435A1 (en) 2012-05-11 2015-04-30 Yale University Compounds useful for promoting protein degradation and methods using same
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
NZ631477A (en) 2012-05-30 2016-12-23 Hoffmann La Roche Substituted pyrrolidine-2-carboxamides
US9345740B2 (en) 2012-07-10 2016-05-24 Bristol-Myers Squibb Company IAP antagonists
US9371568B2 (en) 2012-07-31 2016-06-21 Novartis Ag Markers associated with human double minute 2 inhibitors
DK2882737T3 (da) * 2012-08-09 2019-05-13 Celgene Corp Fast form af (s)-3-(4-((4-morpholinmethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion hydrochlorid
WO2014025759A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Iap antagonists
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
US9603889B2 (en) 2012-10-02 2017-03-28 Bristol-Myers Squibb Company IAP antagonists
TW201428002A (zh) 2012-11-09 2014-07-16 必治妥美雅史谷比公司 用於抑制細胞凋亡抑制劑之巨環化合物
US9637493B2 (en) 2012-12-20 2017-05-02 Merck Sharp & Dohme Corp. Substituted pyrrolopyrimidines as HDM2 inhibitors
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
NL2011274C2 (en) 2013-08-06 2015-02-09 Illumicare Ip B V 51 Groundbreaking platform technology for specific binding to necrotic cells.
CA2902856C (en) 2013-02-28 2021-02-16 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
AU2014236812B2 (en) 2013-03-14 2018-03-01 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
EP3019517A1 (en) 2013-07-12 2016-05-18 Bristol-Myers Squibb Company Iap antagonists
ES2883289T3 (es) * 2013-12-20 2021-12-07 Astex Therapeutics Ltd Compuestos heterocíclicos bicíclicos y sus usos en terapia
JP2017507964A (ja) 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
AU2015247817C1 (en) 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017011371A1 (en) 2015-07-10 2017-01-19 Arvinas, Inc Mdm2-based modulators of proteolysis and associated methods of use
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016349781A1 (en) 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
KR20180119570A (ko) 2016-03-15 2018-11-02 메리맥 파마슈티컬즈, 인크. 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
US11395820B2 (en) 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
EP3445357B1 (en) 2016-04-22 2021-05-26 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
BR112018075206A2 (pt) * 2016-06-06 2019-03-19 Celgene Corporation tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018053354A1 (en) 2016-09-15 2018-03-22 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
WO2018071606A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
IL290809B2 (en) 2016-11-01 2024-01-01 Arvinas Operations Inc Tau-protein targeting protacs and associated methods of use
CA3042301A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
MX2019007646A (es) 2016-12-23 2019-09-06 Arvinas Operations Inc Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
CN117510491A (zh) 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
AU2018211975B2 (en) 2017-01-26 2022-05-26 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
FI3835298T3 (fi) 2019-12-12 2024-07-29 Accutar Biotechnology Inc Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
AR123492A1 (es) 2020-09-14 2022-12-07 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
CN113816927B (zh) 2021-11-23 2022-02-25 苏州国匡医药科技有限公司 一种arv-471中间体的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102725A1 (en) * 2016-12-01 2018-06-07 Arvinas, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10647698B2 (en) 2016-12-01 2020-05-12 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10899742B1 (en) 2016-12-01 2021-01-26 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BYRN, S. ET AL.: "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, 1995, pages 945 - 954, XP055531015, Retrieved from the Internet <URL:https://link.springer.com/article/10.1023/A:1016241927429> DOI: 10.1023/A:1016241927429 *
KROENKE ET AL., SCIENCE, vol. 343, 2014, pages 301

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12172981B2 (en) 2016-12-01 2024-12-24 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
US12162859B2 (en) 2020-09-14 2024-12-10 Arvinas Operations, Inc. Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
CN117229286A (zh) * 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
WO2023241598A1 (zh) * 2022-06-14 2023-12-21 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
WO2024258856A1 (en) * 2023-06-12 2024-12-19 Arvinas Operations, Inc. Solid oral dosage forms of estrogen receptor degraders
WO2025245032A1 (en) 2024-05-20 2025-11-27 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
WO2026018182A1 (en) 2024-07-19 2026-01-22 Pfizer Inc. Process for preparing a cis-1,2-diaryltetralin derivative

Also Published As

Publication number Publication date
US20250059168A1 (en) 2025-02-20
EP4211128A1 (en) 2023-07-19
AR123492A1 (es) 2022-12-07
JP2023541434A (ja) 2023-10-02
MX2023002979A (es) 2023-04-10
AU2021342287A1 (en) 2023-04-13
IL301155A (en) 2023-05-01
BR112023004656A2 (pt) 2023-05-09
CN116390916A (zh) 2023-07-04
CL2023000712A1 (es) 2023-10-20
CA3194954A1 (en) 2022-03-17
TW202214236A (zh) 2022-04-16
KR20230069144A (ko) 2023-05-18
US12162859B2 (en) 2024-12-10
CR20230162A (es) 2023-06-02
PE20231555A1 (es) 2023-10-03
CO2023004435A2 (es) 2023-04-27
ECSP23027481A (es) 2023-07-31
US20220081416A1 (en) 2022-03-17
RS20230288A1 (sr) 2023-06-30
DOP2023000052A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
US12162859B2 (en) Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
CN114667147B (zh) 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
CN1158274C (zh) 苯并吡喃类化合物及其使用方法
CN102858762A (zh) 用于制备药物组合物的新的盐
CN101166736B (zh) 他那普戈特的多晶型ⅱ
EP3077392B1 (en) Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl - 2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof
JP2022553833A (ja) エストロゲン受容体調節薬の塩及び形態
CN101711756B (zh) 3-苯基-3-(4-硝基苯胺基)-1-(4-氯苯基)-1-丙酮制备治疗和/或预防雄激素受体相关疾病的药物的用途
KR100419404B1 (ko) 공지된 브라디키닌 길항제의 유리질 형태
CA3207378A1 (en) Crystalline forms of a somatostatin modulator
OA21441A (en) Crystalline forms of a compound for the targeted degradation of estrogen receptor
JP7316362B2 (ja) Ｎ－芳香族アミド系化合物及びその製造方法と用途
WO2013053287A1 (zh) 一种丁苯酞的衍生物及其制法和用途
CN114349745B (zh) 一种用于治疗心肌缺血的药物及其制备方法
WO2017041622A1 (zh) 一种雄性激素受体抑制剂的结晶形式及其制备方法
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
US9193711B2 (en) SERMs for the treatment of estrogen receptor-mediated disorders
TWI659041B (zh) 類固醇樣化合物之多晶型形式以及其製備方法及用途
SK286346B6 (en) Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
JP2019006762A (ja) 骨成長のためのオキシステロール−スタチン化合物
HK40114445A (zh) 1-(3-氨基吡咯烷-1-羰基)-3，4-二苯基苯化合物的苯甲酸盐的制备方法
WO2023208187A1 (zh) 一种具备抗雄激素受体活性的化合物及其用途
HK40061155A (en) Amorphous pi3k inhibitor and pharmaceutical composition comprising same
HK40022857B (zh) 用於治疗性和/或预防性治疗癌症的化合物
JP2021522341A (ja) イソキノリノンの多形及びアモルファス形態ならびにその使用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21787193

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3194954

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2023516491

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023004656

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202317022511

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 16201

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 20237011950

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2023/0004435

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2021342287

Country of ref document: AU

Date of ref document: 20210913

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: NC2023/0004435

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2021787193

Country of ref document: EP

Effective date: 20230414

ENP Entry into the national phase

Ref document number: 112023004656

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230313

WWE Wipo information: entry into national phase

Ref document number: 523442960

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 523442960

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 523442960

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 523442960

Country of ref document: SA

WWW Wipo information: withdrawn in national office

Ref document number: 797955

Country of ref document: NZ